Journal
PHARMACOGENOMICS
Volume 12, Issue 11, Pages 1571-1585Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.11.114
Keywords
anti-TNF; anti-TNF response; Crohn's disease; gene expression; genetic; genomic; rheumatoid arthritis; serum biomarkers; ulcerative colitis
Categories
Ask authors/readers for more resources
The introduction of anti-TNF therapy has dramatically improved the outlook for patients suffering from a number of inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease. Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. Treatment response is likely to be multifactorial; however, variation in genes or their expression may identify those most likely to respond. By targeted testing of variants within candidate genes, potential predictors of anti-TNF response have been reported; however, very few markers have replicated consistently between studies. Emerging genome-wide association studies suggest that there may be a number of genes with modest effects on treatment response rather than a few genes of large effect. Other potential serum biomarkers of response have also been explored including cytokines and autoantibodies, with antibodies developing to the anti-TNF drugs themselves being correlated with treatment failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available